

Market Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
SYDNEY NSW 2000

**Paradigm Biopharmaceuticals Limited (PAR) - Results of September 2025
Extraordinary General Meeting**

To: Australian Securities Exchange

In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions passed by the shareholders of Paradigm Biopharmaceuticals Limited at its Extraordinary General Meeting held on 23 September 2025.

Authorised for release by the Board of Directors.

Yours faithfully,

Abby Macnish Niven

Company Secretary & CFO

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3).

To learn more please visit: <https://paradigmbiopharma.com>

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com

Disclosure of Proxy Votes

Paradigm Biopharmaceuticals Limited

General Meeting

Tuesday, 23 September 2025



GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of prior issue of Placement Shares to Obsidian Global GP, LLC	P	92,999,141	78,198,512 84.09%	14,632,068 15.73%	40,665	168,561 0.18%	80,591,806 84.63%	14,632,068 15.37%	269,165	Carried
2 Ratification of prior issue of Tranche 1 Convertible Notes to Obsidian Global GP, LLC	P	93,003,441	78,174,812 84.06%	14,662,068 15.77%	36,365	166,561 0.18%	80,566,106 84.60%	14,662,068 15.40%	264,865	Carried
3 Approval to issue Tranche 2 Convertible Notes to Obsidian Global GP, LLC	P	93,003,441	78,154,112 84.03%	14,681,268 15.79%	36,365	168,061 0.18%	80,546,906 84.58%	14,681,268 15.42%	264,865	Carried
4 Approval to issue Tranche 3 Convertible Notes to Obsidian Global GP, LLC	P	93,003,441	78,144,347 84.02%	14,691,033 15.80%	36,365	168,061 0.18%	80,537,141 84.57%	14,691,033 15.43%	264,865	Carried
5 Approval to issue Options to Lodge Corporate Pty Ltd	P	92,885,607	89,861,696 96.74%	2,805,850 3.02%	154,199	218,061 0.23%	92,304,490 97.05%	2,805,850 2.95%	382,699	Carried

